Global Orphan Drugs for Adults Production, Demand and Key Producers, 2022-2028

September 2022 | 121 pages | ID: GFFBE9F7EF4CEN
GlobalInfoResearch

Abstracts

This report studies the global Orphan Drugs for Adults demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Orphan Drugs for Adults, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2021 as the base year. This report explores demand trends and competition, as well as details the characteristics of Orphan Drugs for Adults that contribute to its increasing demand across many markets.

The global Orphan Drugs for Adults market size is expected to reach $ million by 2028, rising at a market growth of % CAGR during the forecast period (2022-2028).

Highlights and key features of the study

Global Orphan Drugs for Adults total market, 2017-2028, (USD Million)

Global Orphan Drugs for Adults total market by region & country, CAGR, 2017-2028, (USD Million)

U.S. VS China: Orphan Drugs for Adults total market, key domestic companies and share, (USD Million)

Global Orphan Drugs for Adults revenue by player and market share 2017-2022, (USD Million)

Global Orphan Drugs for Adults total market by Type, CAGR, 2017-2028, (USD Million)

Global Orphan Drugs for Adults total market by Application, CAGR, 2017-2028, (USD Million)

This reports profiles major players in the global Orphan Drugs for Adults market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Abbvie Inc., Orpharma, Amgen Inc., Recordati SpA, Novartis, Celgene, Amryt Pharma Plc., Johnson & Johnson and GSK Plc., etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Orphan Drugs for Adults market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2017-2028 by year with 2021 as the base year, 2022 as the estimate year, and 2028 as the forecast year.

Global Orphan Drugs for Adults Market, By Region:

• United States
• China
• Europe
• Japan
• South Korea
• ASEAN
• India
• Rest of World

Global Orphan Drugs for Adults Market, Segmentation by Type

• Oncology Drugs
• Gastrointestinal Drugs
• Neurology Drugs
• Cardio-vascular Drugs
• Others

Global Orphan Drugs for Adults Market, Segmentation by Application

• Hospital Pharmacies
• Retail pharmacies
• Others

Companies Profiled:

• Abbvie Inc.
• Orpharma
• Amgen Inc.
• Recordati SpA
• Novartis
• Celgene
• Amryt Pharma Plc.
• Johnson & Johnson
• GSK Plc.
• Bristol-Myers Squibb Company
• Roche Holding
• Sanofi
• Takeda
• Pfizer
• Vertex Pharmaceuticals

Key Questions Answered

1. How big is the global Orphan Drugs for Adults market?

2. What is the demand of the global Orphan Drugs for Adults market?

3. What is the year over year growth of the global Orphan Drugs for Adults market?

4. What is the total value of the global Orphan Drugs for Adults market?

5. Who are the major players in the global Orphan Drugs for Adults market?

6. What are the growth factors driving the market demand?

Contents

1 SUPPLY SUMMARY

1.1 Orphan Drugs for Adults Introduction
1.2 World Orphan Drugs for Adults Market Size & Forecast (2017 & 2021 & 2028)
1.3 World Orphan Drugs for Adults Total Market by Region
  1.3.1 World Orphan Drugs for Adults Market Size by Region (2017-2028)
  1.3.2 United States Orphan Drugs for Adults Market Size (2017-2028)
  1.3.3 China Orphan Drugs for Adults Market Size (2017-2028)
  1.3.4 Europe Orphan Drugs for Adults Market Size (2017-2028)
  1.3.5 Japan Orphan Drugs for Adults Market Size (2017-2028)
  1.3.6 South Korea Orphan Drugs for Adults Market Size (2017-2028)
  1.3.7 ASEAN Orphan Drugs for Adults Market Size (2017-2028)
  1.3.8 India Orphan Drugs for Adults Market Size (2017-2028)
1.4 Market Drivers, Restraints and Trends
  1.4.1 Orphan Drugs for Adults Market Drivers
  1.4.2 Factors Affecting Demand
  1.4.3 Orphan Drugs for Adults Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
  1.5.1 Influence of COVID-19
  1.5.2 Influence of Russia-Ukraine War

2 WORLD ORPHAN DRUGS FOR ADULTS COMPANIES COMPETITIVE ANALYSIS

2.1 World Orphan Drugs for Adults Revenue by Player (2017-2022)
2.2 Industry Rank and Concentration Rate (CR)
  2.2.1 Global Orphan Drugs for Adults Industry Rank of Major Players
  2.2.2 Global Concentration Ratios (CR4) for Orphan Drugs for Adults in 2021
  2.2.3 Global Concentration Ratios (CR8) for Orphan Drugs for Adults in 2021
2.3 Orphan Drugs for Adults Company Evaluation Quadrant
2.4 Orphan Drugs for Adults Market: Overall Company Footprint Analysis
  2.4.1 Orphan Drugs for Adults Market: Region Footprint
  2.4.2 Orphan Drugs for Adults Market: Company Product Type Footprint
  2.4.3 Orphan Drugs for Adults Market: Company Product Application Footprint
2.5 Competitive Environment
  2.5.1 Historical Structure of the Industry
  2.5.2 Barriers of Market Entry
  2.5.3 Factors of Competition
2.6 Mergers, Acquisitions Activity

3 UNITED STATES VS CHINA VS REST OF THE WORLD

3.1 United States VS China: Orphan Drugs for Adults Market Comparison
  3.1.1 United States VS China: Orphan Drugs for Adults Market Size Comparison (2017 & 2021 & 2028)
  3.1.2 United States VS China: Orphan Drugs for Adults Market Size Market Share Comparison (2017 & 2021 & 2028)
3.2 United States Orphan Drugs for Adults Major Players and Market Share, 2017-2022
  3.2.1 Major Players of Orphan Drugs for Adults in United States, Headquarters (States, Country)
  3.2.2 United States Orphan Drugs for Adults Revenue by Domestic Player, (2017-2022)
3.3 China Orphan Drugs for Adults Major Players and Market Share, 2017-2022
  3.3.1 Major Players of Orphan Drugs for Adults in China, Headquarters (Province, Country)
  3.3.2 China Orphan Drugs for Adults Revenue by Domestic Player, (2017-2022)
3.4 Rest of World Orphan Drugs for Adults Major Players and Market Share, 2017-2022
  3.4.1 Major Players of Orphan Drugs for Adults in Rest of World, Headquarters (State, Country)
  3.4.2 Rest of World Orphan Drugs for Adults Revenue by Domestic Player, (2017-2022)

4 MARKET ANALYSIS BY TYPE

4.1 World Orphan Drugs for Adults Market Size Overview by Type: 2017 VS 2021 VS 2028
4.2 Segment Introduction by Type
  4.2.1 Oncology Drugs
  4.2.2 Gastrointestinal Drugs
  4.2.3 Neurology Drugs
  4.2.4 Cardio-vascular Drugs
  4.2.5 Others
4.3 Market Segment by Type
  4.3.1 World Orphan Drugs for Adults Market Size by Type (2017-2022)
  4.3.2 World Orphan Drugs for Adults Market Size by Type (2023-2028)
  4.3.3 World Orphan Drugs for Adults Market Size Market Share by Type (2017-2028)

5 MARKET ANALYSIS BY APPLICATION

5.1 World Orphan Drugs for Adults Market Size Overview by Application: 2017 VS 2021 VS 2028
5.2 Segment Introduction by Application
  5.2.1 Hospital Pharmacies
  5.2.2 Retail pharmacies
  5.2.3 Others
5.3 Market Segment by Application
  5.3.1 World Orphan Drugs for Adults Market Size by Application (2017-2022)
  5.3.2 World Orphan Drugs for Adults Market Size by Application (2023-2028)
  5.3.3 World Orphan Drugs for Adults Market Size by Application (2017-2028)

6 COMPANY PROFILES

6.1 Abbvie Inc.
  6.1.1 Abbvie Inc. Details
  6.1.2 Abbvie Inc. Major Business
  6.1.3 Abbvie Inc. Orphan Drugs for Adults Product and Services
  6.1.4 Abbvie Inc. Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2017-2022)
  6.1.5 Abbvie Inc. Recent Developments/Updates
  6.1.6 Abbvie Inc. Competitive Strengths & Weaknesses
6.2 Orpharma
  6.2.1 Orpharma Details
  6.2.2 Orpharma Major Business
  6.2.3 Orpharma Orphan Drugs for Adults Product and Services
  6.2.4 Orpharma Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2017-2022)
  6.2.5 Orpharma Recent Developments/Updates
  6.2.6 Orpharma Competitive Strengths & Weaknesses
6.3 Amgen Inc.
  6.3.1 Amgen Inc. Details
  6.3.2 Amgen Inc. Major Business
  6.3.3 Amgen Inc. Orphan Drugs for Adults Product and Services
  6.3.4 Amgen Inc. Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2017-2022)
  6.3.5 Amgen Inc. Recent Developments/Updates
  6.3.6 Amgen Inc. Competitive Strengths & Weaknesses
6.4 Recordati SpA
  6.4.1 Recordati SpA Details
  6.4.2 Recordati SpA Major Business
  6.4.3 Recordati SpA Orphan Drugs for Adults Product and Services
  6.4.4 Recordati SpA Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2017-2022)
  6.4.5 Recordati SpA Recent Developments/Updates
  6.4.6 Recordati SpA Competitive Strengths & Weaknesses
6.5 Novartis
  6.5.1 Novartis Details
  6.5.2 Novartis Major Business
  6.5.3 Novartis Orphan Drugs for Adults Product and Services
  6.5.4 Novartis Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2017-2022)
  6.5.5 Novartis Recent Developments/Updates
  6.5.6 Novartis Competitive Strengths & Weaknesses
6.6 Celgene
  6.6.1 Celgene Details
  6.6.2 Celgene Major Business
  6.6.3 Celgene Orphan Drugs for Adults Product and Services
  6.6.4 Celgene Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2017-2022)
  6.6.5 Celgene Recent Developments/Updates
  6.6.6 Celgene Competitive Strengths & Weaknesses
6.7 Amryt Pharma Plc.
  6.7.1 Amryt Pharma Plc. Details
  6.7.2 Amryt Pharma Plc. Major Business
  6.7.3 Amryt Pharma Plc. Orphan Drugs for Adults Product and Services
  6.7.4 Amryt Pharma Plc. Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2017-2022)
  6.7.5 Amryt Pharma Plc. Recent Developments/Updates
  6.7.6 Amryt Pharma Plc. Competitive Strengths & Weaknesses
6.8 Johnson & Johnson
  6.8.1 Johnson & Johnson Details
  6.8.2 Johnson & Johnson Major Business
  6.8.3 Johnson & Johnson Orphan Drugs for Adults Product and Services
  6.8.4 Johnson & Johnson Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2017-2022)
  6.8.5 Johnson & Johnson Recent Developments/Updates
  6.8.6 Johnson & Johnson Competitive Strengths & Weaknesses
6.9 GSK Plc.
  6.9.1 GSK Plc. Details
  6.9.2 GSK Plc. Major Business
  6.9.3 GSK Plc. Orphan Drugs for Adults Product and Services
  6.9.4 GSK Plc. Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2017-2022)
  6.9.5 GSK Plc. Recent Developments/Updates
  6.9.6 GSK Plc. Competitive Strengths & Weaknesses
6.10 Bristol-Myers Squibb Company
  6.10.1 Bristol-Myers Squibb Company Details
  6.10.2 Bristol-Myers Squibb Company Major Business
  6.10.3 Bristol-Myers Squibb Company Orphan Drugs for Adults Product and Services
  6.10.4 Bristol-Myers Squibb Company Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2017-2022)
  6.10.5 Bristol-Myers Squibb Company Recent Developments/Updates
  6.10.6 Bristol-Myers Squibb Company Competitive Strengths & Weaknesses
6.11 Roche Holding
  6.11.1 Roche Holding Details
  6.11.2 Roche Holding Major Business
  6.11.3 Roche Holding Orphan Drugs for Adults Product and Services
  6.11.4 Roche Holding Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2017-2022)
  6.11.5 Roche Holding Recent Developments/Updates
  6.11.6 Roche Holding Competitive Strengths & Weaknesses
6.12 Sanofi
  6.12.1 Sanofi Details
  6.12.2 Sanofi Major Business
  6.12.3 Sanofi Orphan Drugs for Adults Product and Services
  6.12.4 Sanofi Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2017-2022)
  6.12.5 Sanofi Recent Developments/Updates
  6.12.6 Sanofi Competitive Strengths & Weaknesses
6.13 Takeda
  6.13.1 Takeda Details
  6.13.2 Takeda Major Business
  6.13.3 Takeda Orphan Drugs for Adults Product and Services
  6.13.4 Takeda Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2017-2022)
  6.13.5 Takeda Recent Developments/Updates
  6.13.6 Takeda Competitive Strengths & Weaknesses
6.14 Pfizer
  6.14.1 Pfizer Details
  6.14.2 Pfizer Major Business
  6.14.3 Pfizer Orphan Drugs for Adults Product and Services
  6.14.4 Pfizer Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2017-2022)
  6.14.5 Pfizer Recent Developments/Updates
  6.14.6 Pfizer Competitive Strengths & Weaknesses
6.15 Vertex Pharmaceuticals
  6.15.1 Vertex Pharmaceuticals Details
  6.15.2 Vertex Pharmaceuticals Major Business
  6.15.3 Vertex Pharmaceuticals Orphan Drugs for Adults Product and Services
  6.15.4 Vertex Pharmaceuticals Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2017-2022)
  6.15.5 Vertex Pharmaceuticals Recent Developments/Updates
  6.15.6 Vertex Pharmaceuticals Competitive Strengths & Weaknesses

7 RAW MATERIAL AND INDUSTRY CHAIN

7.1 Raw Material of Orphan Drugs for Adults and Key Manufacturers
7.2 Orphan Drugs for Adults Manufacturing Costs
7.3 Orphan Drugs for Adults Production Process
7.4 Orphan Drugs for Adults Industrial Chain

8 DISTRIBUTION CHANNEL ANALYSIS

8.1 Distribution Channel Breakdown for Orphan Drugs for Adults Shipments (%): 2017-2028
  8.1.1 Direct Channel
  8.1.2 Indirect Channel
8.2 Orphan Drugs for Adults Typical Distributors
8.3 Orphan Drugs for Adults Typical Customers

9 RESEARCH FINDINGS AND CONCLUSION

10 APPENDIX

10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. World Orphan Drugs for Adults Market Size by Region (2017, 2022 and 2028) & (USD Million)
Table 2. World Orphan Drugs for Adults Market Size by Region (2017-2022) & (USD Million)
Table 3. World Orphan Drugs for Adults Market Size by Region (2023-2028) & (USD Million)
Table 4. World Orphan Drugs for Adults Market Size Market Share by Region (2017-2022)
Table 5. World Orphan Drugs for Adults Market Size Market Share by Region (2023-2028)
Table 6. Major Market Trends
Table 7. World Orphan Drugs for Adults Revenue by Player (2017-2022) & (USD Million)
Table 8. Revenue Market Share of Key Orphan Drugs for Adults Players in 2021
Table 9. World Orphan Drugs for Adults Industry Rank of Major Player, Based on Revenue in 2021
Table 10. Global Orphan Drugs for Adults Company Evaluation Quadrant
Table 11. Head Office of Key Orphan Drugs for Adults Player
Table 12. Orphan Drugs for Adults Market: Company Product Type Footprint
Table 13. Orphan Drugs for Adults Market: Company Product Application Footprint
Table 14. Orphan Drugs for Adults Mergers & Acquisitions Activity
Table 15. United States VS China Orphan Drugs for Adults Market Size Comparison, (2017 & 2021 & 2028) & (USD Million)
Table 16. Major Player of Orphan Drugs for Adults in United States, Headquarters (States, Country)
Table 17. United States Orphan Drugs for Adults Revenue by Domestic Player, (2017-2022) & (USD Million)
Table 18. United States Orphan Drugs for Adults Revenue Market Share by Domestic Player, (2017-2022)
Table 19. Major Player of Orphan Drugs for Adults in China, Company Headquarters (Province, Country)
Table 20. China Orphan Drugs for Adults Revenue by Domestic Player, (2017-2022) & (USD Million)
Table 21. China Orphan Drugs for Adults Revenue Market Share by Domestic Player, (2017-2022)
Table 22. Major Player of Orphan Drugs for Adults in Rest of World, Company Headquarters (State, Country)
Table 23. Rest of World Orphan Drugs for Adults Revenue by Domestic Player, (2017-2022) & (USD Million)
Table 24. Rest of World Orphan Drugs for Adults Revenue Market Share by Domestic Player, (2017-2022)
Table 25. World Orphan Drugs for Adults Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 26. World Orphan Drugs for Adults Revenue by Type (2017-2022) & (USD Million)
Table 27. World Orphan Drugs for Adults Revenue by Type (2023-2028) & (USD Million)
Table 28. World Orphan Drugs for Adults Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 29. World Orphan Drugs for Adults Revenue by Application (2017-2022) & (USD Million)
Table 30. World Orphan Drugs for Adults Revenue by Application (2023-2028) & (USD Million)
Table 31. Abbvie Inc. Basic Information, Manufacturing Base and Competitors
Table 32. Abbvie Inc. Major Business
Table 33. Abbvie Inc. Orphan Drugs for Adults Product and Services
Table 34. Abbvie Inc. Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 35. Abbvie Inc. Recent Developments/Updates
Table 36. Abbvie Inc. Competitive Strengths & Weaknesses
Table 37. Orpharma Basic Information, Manufacturing Base and Competitors
Table 38. Orpharma Major Business
Table 39. Orpharma Orphan Drugs for Adults Product and Services
Table 40. Orpharma Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 41. Orpharma Recent Developments/Updates
Table 42. Orpharma Competitive Strengths & Weaknesses
Table 43. Amgen Inc. Basic Information, Manufacturing Base and Competitors
Table 44. Amgen Inc. Major Business
Table 45. Amgen Inc. Orphan Drugs for Adults Product and Services
Table 46. Amgen Inc. Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 47. Amgen Inc. Recent Developments/Updates
Table 48. Amgen Inc. Competitive Strengths & Weaknesses
Table 49. Recordati SpA Basic Information, Manufacturing Base and Competitors
Table 50. Recordati SpA Major Business
Table 51. Recordati SpA Orphan Drugs for Adults Product and Services
Table 52. Recordati SpA Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 53. Recordati SpA Recent Developments/Updates
Table 54. Recordati SpA Competitive Strengths & Weaknesses
Table 55. Novartis Basic Information, Manufacturing Base and Competitors
Table 56. Novartis Major Business
Table 57. Novartis Orphan Drugs for Adults Product and Services
Table 58. Novartis Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 59. Novartis Recent Developments/Updates
Table 60. Novartis Competitive Strengths & Weaknesses
Table 61. Celgene Basic Information, Manufacturing Base and Competitors
Table 62. Celgene Major Business
Table 63. Celgene Orphan Drugs for Adults Product and Services
Table 64. Celgene Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 65. Celgene Recent Developments/Updates
Table 66. Celgene Competitive Strengths & Weaknesses
Table 67. Amryt Pharma Plc. Basic Information, Manufacturing Base and Competitors
Table 68. Amryt Pharma Plc. Major Business
Table 69. Amryt Pharma Plc. Orphan Drugs for Adults Product and Services
Table 70. Amryt Pharma Plc. Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 71. Amryt Pharma Plc. Recent Developments/Updates
Table 72. Amryt Pharma Plc. Competitive Strengths & Weaknesses
Table 73. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 74. Johnson & Johnson Major Business
Table 75. Johnson & Johnson Orphan Drugs for Adults Product and Services
Table 76. Johnson & Johnson Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 77. Johnson & Johnson Recent Developments/Updates
Table 78. Johnson & Johnson Competitive Strengths & Weaknesses
Table 79. GSK Plc. Basic Information, Manufacturing Base and Competitors
Table 80. GSK Plc. Major Business
Table 81. GSK Plc. Orphan Drugs for Adults Product and Services
Table 82. GSK Plc. Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 83. GSK Plc. Recent Developments/Updates
Table 84. GSK Plc. Competitive Strengths & Weaknesses
Table 85. Bristol-Myers Squibb Company Basic Information, Manufacturing Base and Competitors
Table 86. Bristol-Myers Squibb Company Major Business
Table 87. Bristol-Myers Squibb Company Orphan Drugs for Adults Product and Services
Table 88. Bristol-Myers Squibb Company Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 89. Bristol-Myers Squibb Company Recent Developments/Updates
Table 90. Bristol-Myers Squibb Company Competitive Strengths & Weaknesses
Table 91. Roche Holding Basic Information, Manufacturing Base and Competitors
Table 92. Roche Holding Major Business
Table 93. Roche Holding Orphan Drugs for Adults Product and Services
Table 94. Roche Holding Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 95. Roche Holding Recent Developments/Updates
Table 96. Roche Holding Competitive Strengths & Weaknesses
Table 97. Sanofi Basic Information, Manufacturing Base and Competitors
Table 98. Sanofi Major Business
Table 99. Sanofi Orphan Drugs for Adults Product and Services
Table 100. Sanofi Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 101. Sanofi Recent Developments/Updates
Table 102. Sanofi Competitive Strengths & Weaknesses
Table 103. Takeda Basic Information, Manufacturing Base and Competitors
Table 104. Takeda Major Business
Table 105. Takeda Orphan Drugs for Adults Product and Services
Table 106. Takeda Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 107. Takeda Recent Developments/Updates
Table 108. Takeda Competitive Strengths & Weaknesses
Table 109. Pfizer Basic Information, Manufacturing Base and Competitors
Table 110. Pfizer Major Business
Table 111. Pfizer Orphan Drugs for Adults Product and Services
Table 112. Pfizer Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 113. Pfizer Recent Developments/Updates
Table 114. Vertex Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 115. Vertex Pharmaceuticals Major Business
Table 116. Vertex Pharmaceuticals Orphan Drugs for Adults Product and Services
Table 117. Vertex Pharmaceuticals Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 118. Orphan Drugs for Adults Raw Material
Table 119. Key Manufacturers of Orphan Drugs for Adults Raw Materials
Table 120. Orphan Drugs for Adults Typical Distributors
Table 121. Orphan Drugs for Adults Typical Customers

List Of Figures

LIST OF FIGURES

Figure 1. Orphan Drugs for Adults Picture
Figure 2. World Orphan Drugs for Adults Total Market Size: 2017 & 2021 & 2028, (USD Million)
Figure 3. World Orphan Drugs for Adults Total Market Size (2017-2028) & (USD Million)
Figure 4. World Orphan Drugs for Adults Market Size Market Share by Region (2017-2028)
Figure 5. United States Orphan Drugs for Adults Market Size (2017-2028) & (USD Million)
Figure 6. China Orphan Drugs for Adults Market Size (2017-2028) & (USD Million)
Figure 7. Europe Orphan Drugs for Adults Market Size (2017-2028) & (USD Million)
Figure 8. Japan Orphan Drugs for Adults Market Size (2017-2028) & (USD Million)
Figure 9. South Korea Orphan Drugs for Adults Market Size (2017-2028) & (USD Million)
Figure 10. ASEAN Orphan Drugs for Adults Market Size (2017-2028) & (USD Million)
Figure 11. India Orphan Drugs for Adults Market Size (2017-2028) & (USD Million)
Figure 12. Orphan Drugs for Adults Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. Producer Shipments of Orphan Drugs for Adults by Player Revenue ($MM) and Market Share (%): 2021
Figure 15. Global Four-firm Concentration Ratios (CR4) for Orphan Drugs for Adults Markets in 2021
Figure 16. Global Four-firm Concentration Ratios (CR8) for Orphan Drugs for Adults Markets in 2021
Figure 17. United States VS China: Orphan Drugs for Adults Market Size Market Share Comparison (2017 & 2021 & 2028)
Figure 18. World Orphan Drugs for Adults Market Size by Type, (USD Million), 2017 & 2021 & 2028
Figure 19. World Orphan Drugs for Adults Market Size Market Share by Type in 2021
Figure 20. Oncology Drugs
Figure 21. Gastrointestinal Drugs
Figure 22. Neurology Drugs
Figure 23. Cardio-vascular Drugs
Figure 24. Others
Figure 25. World Orphan Drugs for Adults Market Size Market Share by Type (2017-2028)
Figure 26. World Orphan Drugs for Adults Market Size by Application, (USD Million), 2017 & 2021 & 2028
Figure 27. World Orphan Drugs for Adults Market Size Market Share by Application in 2021
Figure 28. Hospital Pharmacies
Figure 29. Retail pharmacies
Figure 30. Others
Figure 31. World Orphan Drugs for Adults Market Size Market Share by Application (2017-2028)
Figure 32. Manufacturing Cost Structure Analysis of Orphan Drugs for Adults in 2021
Figure 33. Manufacturing Process Analysis of Orphan Drugs for Adults
Figure 34. Orphan Drugs for Adults Industrial Chain
Figure 35. Distribution Channel Breakdown for Orphan Drugs for Adults Shipments (%): 2017-2028
Figure 36. Direct Channel Pros & Cons
Figure 37. Indirect Channel Pros & Cons
Figure 38. Methodology
Figure 39. Research Process and Data Source